Enhancing MRI Efficiency and Quality: Can the New SIGNA Experience Have an Impact?
Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.
Offering the potential benefits of streamlined scanning and intelligent automation in magnetic resonance imaging (MRI), GE Healthcare recently launched the SIGNA Experience, which combines imaging software, artificial intelligence (AI) applications and automated workflow technologies into one platform.
GE Healthcare said the four primary components of the SIGNA Experience include enhanced image quality through the next-generation imaging software SIGNA One (available on SIGNA Prime); deep learning AI applications (including AIR Recon DL) that facilitate shorter scan times and improved signal-to-noise (SNR) ratios; flexible, lightweight AIR Coils; and automated workflow technologies, such as AIRTouch, that simplify scan set-up.
The SIGNA Experience also offers visually highlighted fields for step-by-step guidance, minimal clicks to complete the MRI exam and an intuitive workflow that accommodates a variety of experience levels, according to GE Healthcare.
“SIGNA Experience was designed in response to today’s industry pressures to help achieve operational efficiency and simplicity as clinicians face a significant volume of non-urgent backlog scans caused largely by the impact of COVID-19, radiologist shortages and staff burnout,” explained Jie Xue, the president, and CEO of Magnetic Resonance for GE Healthcare. “These technologies enable scanner operators of all skill levels to get the job done without compromising quality and output.”
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
